Samsung Biologics’ workers and management jointly launched a donation program in affiliation with stores and restaurants in ...

Samsung Biologics has established a corporate social responsibility program that applies 5 to 15 percent of its employees' ...

Samsung Biologics has promoted Kevin Sharp, head of its New Jersey office leading global sales, to executive vice president, ...

Samsung Biologics has introduced a new charity program designed to assist children in need, in cooperation with neighboring ...

On the back of several strong quarters and a year already chock-full of manufacturing accords, Korean CDMO Samsung Biologics is adding yet another project to its contract manufacturing Rolodex.

Samsung Biologics said on Wednesday it surpassed the 5 trillion won ($3.59 billion) mark in its accumulated orders this year ...

INCHEON, South Korea, Dec. 3, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its second Supplier ESG Day ...

Samsung Biologics has now partnered with 17 of the world's top 20 pharmaceutical companies and continues to extend contracts with existing clients to support them in advancing innovative therapies.

Upon completion, the company will secure a manufacturing capacity of 784,000 liters (828,000 quarts) per year, moving closer to its production capacitygoal of 1.32 million liters per year by 2032. It ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced a ...